Literature DB >> 20952479

Systemic vasculitis in patients with hepatitis C virus infection with and without detectable mixed cryoglobulinemia.

Benjamin Terrier1, Damien Sène, Agnès Dechartres, David Saadoun, Nicolas Ortonne, Philippe Rouvier, Lucile Musset, Matthieu Resche Rigon, Thierry Maisonobe, Patrice Cacoub.   

Abstract

OBJECTIVE: to describe hepatitis C virus (HCV)-related systemic vasculitis in patients without detectable mixed cryoglobulinemia (MC) and to compare them to typical cases of HCV-MC vasculitis.
METHODS: twelve HCV RNA+ patients with histologically proven vasculitis in the absence of detectable MC (cases) were retrospectively compared with 48 HCV RNA+ patients with MC vasculitis (controls). Each case was matched with 4 controls for age and sex.
RESULTS: the main epidemiological and virologic features were similar between cases and controls. No clinical difference was found, except for lower rates of arthralgias (33% vs 71%; p = 0.02) and purpura (50% vs 83%; p = 0.03) in cases. Cases showed higher mean serum C3 (1.17 ± 0.21 vs 0.93 ± 0.23 g/l; p = 0.01) and median C4 levels (0.25 vs 0.04 g/l; p < 0.001), lower median serum IgM levels (0.6 vs 1.9 g/l; p < 0.001), and lower rates of rheumatoid factor positivity (8% vs 82%; p < 0.001) than controls. The main histologic features were similar between cases and controls. Immunofluorescence analysis of skin biopsy from 1 case revealed perivascular deposits of C3 and IgA. After treatment, overall clinical response of vasculitis (75% vs 83%) and sustained virological response (40% vs 64%; p = 0.3) were similar between cases and controls, except for higher complete clinical response (42% vs 73%; p = 0.05) in controls.
CONCLUSION: HCV-related systemic vasculitis may occur in the absence of detectable MC. Our findings suggest that such vasculitis probably results from immune complex-mediated mechanisms, and that the therapeutic management of such vasculitis should be similar to that of HCV-MC vasculitis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20952479     DOI: 10.3899/jrheum.100191

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  6 in total

1.  Local treatment of non healing leg ulcers in a patient with hepatitis C virus infection.

Authors:  Maria G Onesti; Paolo Fioramonti; Diego Massera; Vittoria Amorosi; Pasquale Fino
Journal:  Int Wound J       Date:  2013-06-11       Impact factor: 3.315

Review 2.  [Leg discoloration].

Authors:  L Unger; U Wollina; J Machetanz; C Stelzner; S Schellong
Journal:  Internist (Berl)       Date:  2013-11       Impact factor: 0.743

Review 3.  Neurological complications of hepatitis C infection.

Authors:  Micheline McCarthy; Melissa R Ortega
Journal:  Curr Neurol Neurosci Rep       Date:  2012-12       Impact factor: 5.081

4.  Hepatitis C virus-host interactions: Etiopathogenesis and therapeutic strategies.

Authors:  Mohamed Hassan; Denis Selimovic; Abdelouahid El-Khattouti; Hanan Ghozlan; Youssef Haikel; Ola Abdelkader
Journal:  World J Exp Med       Date:  2012-04-20

5.  Hepatitis C virus induced endothelial inflammatory response depends on the functional expression of TNFα receptor subtype 2.

Authors:  Joachim Pircher; Thomas Czermak; Monika Merkle; Hanna Mannell; Florian Krötz; Andrea Ribeiro; Volker Vielhauer; Jonathan Nadjiri; Erik Gaitzsch; Markus Niemeyer; Stefan Porubsky; Hermann-Josef Gröne; Markus Wörnle
Journal:  PLoS One       Date:  2014-11-24       Impact factor: 3.240

6.  Efficacy and safety of rituximab in the treatment of vasculitic leg ulcers associated with hepatitis C virus infection.

Authors:  Fabio Bonilla-Abadía; Andrés F Echeverri; Jorge H Izquierdo; Felipe Cañas; Carlos A Cañas
Journal:  Case Rep Rheumatol       Date:  2012-12-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.